Tumours develop and progress through an interplay between cancer cells and the stroma. The tumour stroma or tumour microenvironment (TME) harbours many different cell types including endothelial and lymphatic cells, pericytes, various immune cells and fibroblasts embedded in an extracellular matrix (ECM). Both the epithelial cancer compartment and the TME produce a plethora of soluble factors, different types of vesicles, matrix components and matrix-modifying enzymes that promote cancer cell survival, migration, invasion and dissemination ([@bib22]; [@bib11]).

Among the secreted factors involved in the paracrine tumour cross-talk are chemokines; small proteins of about 8--14 kDa that act both in an autocrine and in a paracrine manner and exert local and systemic effects. Chemokines create a gradient along which cells, expressing the corresponding receptors, travel to the source of this gradient. Thus, tumour-derived chemokines have a crucial role in the recruitment of different cell types into the tumour and in their subsequent activation. Chemokines have been demonstrated to exert potent pro- and anti-tumorigenic effects, depending on the context. For example, certain chemokines stimulate tumour growth and invasion of cancer cells and promote angiogenesis, while other chemokines inhibit angiogenesis by sequestering pro-angiogenic factors ([@bib19]; [@bib30]; [@bib4]). Chemokines also mobilise and recruit different bone marrow-derived cells and activate stromal cells in sites of inflammation, primary tumours or metastasis ([@bib6]; [@bib16]).

The orphan chemokine CXCL14, earlier designated BRAK, MIP-2*γ*, BMAC or KS1, displays chemotactic activity towards immature dendritic cells, monocytes, macrophages and NK cells but not T cells ([@bib28]; [@bib15]; [@bib26]; [@bib27]; [@bib29]). Enhanced expression of CXCL14 has been found in different types of cancer, including tumours arising in colon, pancreas, prostate and breast, where CXCL14 is expressed by cancer cells or stromal cells or by both cell types ([@bib2]; [@bib25]; [@bib35]; [@bib36]). However, in lung cancer CXCL14 is epigenetically silenced, and re-activation of CXCL14 expression in tumour cells suppressed tumour growth in xenograft models ([@bib32]). As other chemokines, CXCL14 has shown context-dependent pro- or anti-tumoral effects in experimental models systems, as recently discussed by [@bib13]. Some findings suggest that the net-effects of CXCL14 on tumour growth depend on the cell type expressing this factor. For example, in animal models CXCL14 promotes the growth of breast and prostate tumours when expressed by stromal fibroblasts but shows anti-tumoral effects when expressed by the malignant cells ([@bib2]; [@bib25]; [@bib12]; [@bib5]). The tumour stimulatory effects of stroma-derived CXCL14 are suggested to include pro-angiogenic effects and its ability to recruit monocytes to tumours ([@bib4]). Notably, the clinical significance of these findings remains to be further characterised by high-resolution analysis of CXCL14 expression in human tumour samples.

There are only a few studies so far that have investigated the potential prognostic value of CXCL14 expression in cancer, by analysing protein expression in whole tumour tissue using immunohistochemistry (IHC). Most of these analyses demonstrated that high CXCL14 protein levels in tumours correlate with a more favourable prognosis ([@bib12]; [@bib17]; [@bib24]). Importantly, these earlier IHC studies have not addressed the possibility that the prognostic impact of CXCL14 may be determined by the tumour compartment in which CXCL14 is produced.

In light of these experimental and early clinical findings this study aimed at characterising, in a compartment-specific manner, CXCL14 expression in human breast cancer and to explore potential links to clinicopathological characteristics and outcome.

Materials and methods
=====================

Paraffin embedding of cultured fibroblasts and xenograft tumours
----------------------------------------------------------------

Previously established fibroblasts overexpressing CXCL14 (NIH-CXCL14) and control fibroblasts (NIH-ctr) ([@bib4]) were cultured in DMEM supplemented with 10% fetal calf serum (Sigma-Aldrich, Stockholm, Sweden), 1% glutamine and antibiotics (penicillin (100 units per ml, Sigma-Aldrich) and streptomycin (100 *μ*g ml^−1^, Sigma-Aldrich)). Equal number of cells were harvested, centrifuged at 1500 r.p.m. for 5 min and fixed overnight with 4% paraformaldehyde (Sigma-Aldrich). Xenograft tumours from co-injection experiments of MCF7 cells and NIH-CXCL14 fibroblasts or NIH-ctr fibroblasts into SCID mice have been described previously ([@bib5]).

Cell pellets and xenograft tumours were placed in tissue embedding boxes in 70% ethanol and dehydrated using increasing percentages of ethanol, followed by paraffin embedding and sectioning on Superfrost Plus slides (Menzel-Gläser, Braunschweig, Germany).

Tumour collection and tissue microarray
---------------------------------------

The breast cancer tissue microarray (TMA) was made from a consecutive series of tumours from 498 primary breast cancer patients diagnosed at the Department of Pathology, Malmö University Hospital between 1988 and 1992. Tissue was prepared and fixed in 10% natural buffered formalin (NBF) for 6--72 h. The median age at diagnosis was 64.2 years (range, 27--96 years), and follow-up data on recurrence-free survival and breast cancer-specific survival were available for 491 and 494 patients, respectively. The median follow-up time for patients without breast cancer event was 106 months (range, 0--207 months). Information on adjuvant therapy was available for 389 patients, 157 of these had received adjuvant tamoxifen, 19 adjuvant chemotherapy and 4 patients had received a combination of tamoxifen and chemotherapy. In all, 209 patients did not receive any adjuvant treatment. This cohort is described in detail elsewhere ([@bib7]). Tumours were classified as belonging to the subtype Luminal A, Luminal B, HER2 and Basal-like according to the immunohistochemical expression of oestrogen receptor *α* (ER*α*), progesterone receptor (PR) and epidermal growth factor receptor (EGFR). Tumours negative for ER*α*, PR and HER2 were defined as triple negative breast cancers (TNBC). The tumour stroma abundance was determined by semi-quantative scoring of hematoxylin and eosin-stained sections.

CXCL14 RNAscope 2.0 Assay
-------------------------

The RNAscope 2.0 Assay, with a CXCL14-specific probe (Advanced Cell Diagnostics, Hayward, CA, USA), was used for detection of CXCL14 mRNA on the breast tumour TMA. A detailed description of the RNAscope 2.0 Assay has been published before ([@bib33]). In short, tissue sections were deparaffinised in xylene followed by dehydration with 100% ethanol. The sections were air-dried and incubated with pretreatment 1 solution for 15 min at room temperature and washed with distilled water. Pretreatment was continued by boiling the slides in pretreatment buffer 2 for 15 min, and the slides were immediately washed with distilled water, followed by 100% ethanol and then air-dried. Pretreatment buffer 3 was added to the tissue sections, and incubation was performed in a humidity chamber at 40 °C for 30 min. Slides were washed in distilled water and hybridisation was initiated. The CXCL14 probe (Advanced Cell Diagnostics) was added, and the slides were hybridised in a humidity chamber at 40 °C for 2 h, followed by incubation with Amp1--Amp6. Hybridisation with Amp1 and Amp2 was done at 40 °C for 30 min and 15 min, respectively. Amp3 and Amp4 hybridisation was also performed at 40 °C for 30 min and 15 min, respectively. The slides were incubated with Amp5 and Amp6 at room temperature for 30 min and 15 min, respectively. Slides were washed in 1 × wash buffer after each step. Detection was performed using DAB followed by haematoxylin counterstaining (Histolab Products AB, Gothenburg, Sweden), dehydration and mounting with Vectamount permanent mounting media (Vector Laboratories, Inc., Burlingame, CA, USA). The CXCL14 mRNA staining was scored blinded as negative or positive with independent scoring of total tumour tissue, epithelial and stromal compartments.

Statistics
----------

The *X*^2^ test was used for analysing association of CXCL14 expression with clinicopathological parameters, including age, tumour size, Nottingham histological grade (NHG), lymph-node metastasis (node status), ER*α*-, PR- and HER2 receptor status and tumour cell proliferation (Ki67 expression), and with breast cancer subtypes (Luminal A, Luminal B, Basal and HER2), tumour stroma abundance and adjuvant therapy.

The Kaplan--Meier method and log-rank test were used to estimate recurrence-free survival and breast cancer-specific survival. Primary events included in the survival analysis were loco-regional recurrence and distant metastasis for recurrence-free survival, and breast cancer-specific death. Contralateral events and non-breast cancer-specific deaths were excluded.

Cox proportional hazards model was used for comparing hazard ratios (HRs) in both univariable and multivariable analyses. Multivariable analyses included known prognostic- and therapy predictive factors, such as age, tumour size, NHG, node status, ER*α*- and HER2 receptor status. The results are presented as HRs including their 95% confidence intervals (CIs). Cox proportional hazards model was further used for analysis of the impact of stromal CXCL14 on survival in different patient subsets.

Two-sided statistical tests were performed and *P*-values below 0.05 were considered as significant. All calculations were performed with the statistical package SPSS 21.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

CXCL14 is differentially expressed in the stromal and epithelial compartments of breast cancer
----------------------------------------------------------------------------------------------

To describe CXCL14 expression in human breast tumour tissue, a clinically well-annotated TMA with tumours from 498 patients was stained for CXCL14 mRNA using the RNAscope 2.0 Assay ([@bib33]).

The specificity of the CXCL14 probe (Advanced Cell Diagnostics) was evaluated on sections of paraffin-embedded pellets of fibroblasts overexpressing CXCL14 or control fibroblasts, and on xenograft tumours containing MCF7 breast cancer cells and CXCL14 fibroblasts or control fibroblasts ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), that have been explored in previous studies ([@bib4], [@bib5]). For analyses of the clinical samples, CXCL14 staining was scored as negative or positive in total tumour tissue and separately in the epithelial and stromal compartments ([Figure 1](#fig1){ref-type="fig"}). Scoring was done blinded with regard to clinic-pathological characteristics and outcome.

Of the 498 patient samples represented on the TMA, 394 (79%) yielded informative staining and were included in the subsequent analyses ([Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Among these patient biopsies, 138 (35%) were positive for CXCL14 mRNA. Among these, 31 patients (22%) showed positivity in both compartments, 48 patients (35%) showed staining only in the epithelium and 59 patients (43%) displayed positivity only in the tumour stroma. Together, these data demonstrate that breast cancer tissue in general displays variable expression of CXCL14 mRNA, and that expression in the stromal and epithelial compartments is independent.

Epithelial and stromal CXCL14 expression shows different associations with clinicopathological characteristics
--------------------------------------------------------------------------------------------------------------

To explore the clinical relevance of CXCL14 in breast cancer, associations between clinicopathological characteristics (age, tumour size, NHG, node status, ER*α*-, PR and HER2 receptor status, tumour cell proliferation), breast cancer subtypes (Luminal A, Luminal B, HER2, Basal), adjuvant treatment or tumour stroma abundance and total, epithelial or stromal CXCL14 expression were analysed ([Table 1](#tbl1){ref-type="table"}).

Epithelial CXCL14 was significantly associated with ER*α* positivity (*P*=0.006) and with decreased proliferation, determined by Ki67 expression (*P*=0.049) ([Table 1](#tbl1){ref-type="table"}). Concerning stromal CXCL14, trends were observed for associations with positive lymph-node status and age \>50 years. However, neither stromal nor total CXCL14 expression correlated significantly with any tumour or patient characteristics. Notably, stromal CXCL14 expression was not associated with the amount of tumour stroma ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

In summary, epithelial CXCL14 expression is significantly associated with ER*α* positivity and low proliferation, whereas stromal CXCL14 expression is not linked to any of the established clinicopathological parameters, subtypes of breast cancer or tumour stroma abundance.

High stromal CXCL14 expression correlates with shorter recurrence-free and breast cancer-specific survival
----------------------------------------------------------------------------------------------------------

The results from the CXCL14 expression analyses were combined with patient survival data to explore the potential impact of the marker on outcome. Three sets of independent analyses were performed where breast cancer patients were categorised based on the total CXCL14 expression, the epithelial CXCL14 expression or the stromal CXCL14 expression.

As shown in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}, Kaplan--Meier analysis revealed that the group with high total CXCL14 expression displayed a significantly shorter breast cancer-specific survival (*P*=0.014) and recurrence-free survival (*P*=0.028). To investigate the impact of compartment-specific expression of CXCL14 on breast cancer outcome, similar analyses were performed for epithelial and stromal expression separately. Of note, high stromal CXCL14, but not epithelial CXCL14, was linked to decreased breast cancer-specific survival (*P*=0.001) and decreased recurrence-free survival (*P*=0.004) ([Figure 2](#fig2){ref-type="fig"}). Also according to a Cox proportional hazard model, the presence of CXCL14 transcripts in the tumour stroma increased both the risk for breast cancer-specific death (HR=2.22 (1.40--3.52) (95% CI)) and the risk for recurrence (HR=1.76 (1.19--2.58) (95% CI)).

To investigate whether the prognostic significance of stromal CXCL14 was particularly strong in certain patient subsets, survival analyses were performed in strata. As shown in [Figure 3](#fig3){ref-type="fig"}, the impact of stromal CXCL14 expression on breast cancer-specific survival was particularly prominent in patients with ER*α* negative, triple negative and basal-like tumours (HR=3.50, HR=5.08 and HR=3.58, respectively). Similar results were obtained in subset analyses using recurrence-free survival as end point ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

These analyses thus demonstrate significant links between breast cancer survival and total as well as stromal CXCL14 expression. On the basis of explorative sub-set analyses, the survival association for stromal CXCL14 expression was particularly prominent in patients of the ER*α* negative-, triple negative and basal subgroups.

CXCL14 expression in the tumour stroma is an independent marker of poor prognosis in breast cancer
--------------------------------------------------------------------------------------------------

The findings of associations between CXCL14 expression and survival prompted further analyses to investigate whether CXCL14 also acts as an independent marker for breast cancer survival. Multivariable analyses were performed including, in addition to CXCL14 status, age, tumour size, NHG, node status, ER*α*- and HER2 status. Separate analyses were done for total CXCL14 and stromal CXCL14 expression ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

These analyses demonstrated that stromal CXCL14 is an independent marker for breast cancer-specific and recurrence-free survival. Stromal CXCL14 expression was shown to be the third strongest prognostic factor (HR=1.877 for breast cancer-specific survival), with lymph-node positivity and histological grade as the other factors with a higher HR ([Table 2](#tbl2){ref-type="table"}). Analyses based on total CXCL14 yielded similar results (HR=1.860 for breast cancer-specific survival) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Stromal CXCL14 expression remained significantly associated with survival in multivariable analysis when adjusted for stroma abundance (data not shown).

These analyses thus identify stromal CXCL14 as a candidate novel independent marker for breast cancer survival.

Discussion
==========

The present study identifies stromal CXCL14 expression as an independent novel marker for decreased breast cancer-specific survival and decreased recurrence-free survival, in particular in ER*α* negative-, triple negative and basal-like breast cancers. In contrast, CXCL14 expression in malignant cells did not show a correlation to clinical outcome. These findings add to a series of recent studies demonstrating prognostic significance of stroma-expressed marker proteins and stroma-related gene-signatures ([@bib20]). Notably, findings have general novelty in the demonstration of prognostic significance of a stroma-derived secreted factor.

The findings of associations between stromal CXCL14 expression and an impaired survival are consistent with some earlier studies. *CXCL14* was found to be part of gene expression signatures that predict worse disease-free survival of prostate and ovarian cancer ([@bib23]; [@bib36]). In breast cancer, the *CXCL14* gene was included in a gene signature that significantly correlated with the presence of clinical metastasis ([@bib8]). By analysing CXCL14 protein expression, [@bib37] found the chemokine to be upregulated in colorectal tumour tissue, as compared with normal adjacent colorectal mucosa. In this study, CXCL14 was found to be associated with tumour-node metastasis (TNM) stage, differentiation grade and tumour size, and to correlate with disease recurrence and worse overall survival ([@bib37]). Other studies have instead reported on associations between high CXCL14 protein expression and good prognosis in breast and colorectal cancer ([@bib12]; [@bib17]). Notably, none of these studies considered the cell type responsible for CXCL14 expression.

Immunohistochemistry does not allow determination of the cellular origin of secreted proteins within tissues. As CXCL14 is a secreted protein, we established the RNAscope 2.0 Assay that allows monitoring of CXCL14 mRNA in cells and tissue ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). By detecting the CXCL14 mRNA, we are able to track the cell type producing the CXCL14 protein.

RNAscope is an *in situ* analysis technique developed for analysis of formalin-fixed paraffin-embedded tissue (FFPE) material. The partial degradation of RNA in FFPE tissues is accounted for by the use of 20 target probe pairs, spanning 40--50 nucleotides along the target RNA molecule. Furthermore, RNAscope is designed to amplify target-specific signals without amplification of background signals ([@bib33]). However, pre-analytical variables including time from tumour acquisition to fixation, use of fixatives and fixation time impact on the RNA quality. The pre-analytical conditions used in this study follow standardised guidelines. However, the exact time intervals were not documented and cannot be guaranteed for all tumour samples, which is recognised as a limitation of the tumour material of this study.

Profiling of normal and tumour stroma of breast and prostate tissue has previously identified activated fibroblasts, a prominent cell type of the tumour stroma, as a source for CXCL14 ([@bib2]; [@bib4]). Compartment-specific effects of CXCL14 are suggested by findings from experimental studies. In mouse models of breast and prostate cancer, fibroblast-derived CXCL14 was shown to enhance tumour growth through NOS-dependent mechanisms that involve stimulation of angiogenesis and macrophage recruitment ([@bib4], [@bib5]). In contrast, anti-tumoral effects of CXCL14 have been observed in model systems where expression in malignant cells has been manipulated ([@bib12]). Notably, epithelial CXCL14 expression showed a significant association with decreased proliferation in the breast cancer samples analysed in the present study ([Table 1](#tbl1){ref-type="table"}). These types of context-dependent effects have also been described for other chemokines including CCL5 and CXCL12 in model systems ([@bib19]; [@bib34]; [@bib14]; [@bib1]). Tumour cell expression of CXCL12 showed tumour inhibiting activities in breast cancer model systems, whereas CXCL12 from fibroblasts promoted breast tumour growth *in vivo* by mechanisms that involved modulation of a tumour promoting stroma ([@bib19]; [@bib34]; [@bib14]). Notably, the prognostic impact of chemokines and their receptors has also been shown to vary depending on the cell types that they are expressed in ([@bib18]).

In the present study, CXCL14 expression showed no association with tumour characteristics used to predict outcome or treatment response, which indicates that stromal CXCL14 adds additional value in defining a subgroup of breast cancer patients with poor prognosis. This notion is further supported by the finding that stroma-derived CXCL14 is a prognostic factor for breast cancer independently of, for example, tumour stage, ER*α*- status and presence of lymph-node metastasis in multivariable analysis. In addition, stromal CXCL14 expression was not associated with the abundance of tumour stroma, suggesting that the type of tumour stroma rather than the amount of stroma is important for breast cancer survival. In concordance, other marker proteins, including *α*SMA, PDGFR*β*, FAP, Caveolin-1, and CAF-gene expression signatures that define the type of tumour stroma have been shown to impact on breast cancer survival ([@bib3]; [@bib31]; [@bib9]; [@bib21]; [@bib10]).

Poor survival of breast cancer is associated with the development of metastasis. The roles of CAF-derived CXCL14 during the biological processes related to metastasis formation, including tumour cell epithelial-to-mesenchymal transition (EMT), migration and invasion, might explain the correlation between stromal CXCL14 and worse breast cancer survival and should be further explored. Furthermore, in the present study the prognostic significance of stromal CXCL14 is more apparent in the ER*α* negative- and triple negative subgroups, suggesting particular relevance for stromal CXCL14 in the progression of these breast cancer subsets. Thus, it will be important to identify the inducer of CXCL14 in these breast cancer subsets, and to further explore the consequences of stromal CXCL14 expression with regard to tumour growth and metastasis. These findings should also prompt therapy-oriented studies, since development of new treatments for these patients is especially urgent due to their lack of sensitivity to hormonal and HER2-directed therapies. CXCL14 should be further explored as a potential target for breast cancer treatment in patients with a prominent CXCL14 expression in the tumour stroma.

Collectively, the findings of the present study should encourage additional studies on the potential of CXCL14 as a breast cancer biomarker. These should be designed to further explore the specific impact of CXCL14 on the natural course of the disease as well as response to different treatments, and should particularly consider the cellular source of CXCL14. The associations of stromal CXCL14 with poor prognosis also suggest additional mechanistic studies where identification of the CXCL14 receptor appears as a prioritised topic.
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###### 

Click here for additional data file.

![**CXCL14 mRNA expression detected with RNAscope in breast tumours.** Examples of negative, epithelial, stromal and both epithelial and stromal staining of CXCL14 mRNA in breast tumours. Black arrows show epithelial CXCL14 expression and white arrows show stromal CXCL14 expression (upper panel). Scale bar: 100 *μ*m. Magnifications of each example (lower panel).](bjc2016104f1){#fig1}

![**Correlations of stromal CXCL14 expression with worse breast cancer-specific and recurrence-free survival in breast cancer patients.** Kaplan--Meier curves for breast cancer-specific survival (BCSS) and recurrence-free survival (RFS) in patients with positive or negative CXCL14 mRNA staining in the tumour stroma (right panel) and in the tumour epithelium (left panel).](bjc2016104f2){#fig2}

![**Subgroup-specific analysis of breast cancer-specific survival for stromal CXCL14 in breast cancer patients.** A forest plot over hazard ratios for breast cancer-specific survival analysed using Cox regression for stromal CXCL14 in different breast cancer subgroups.](bjc2016104f3){#fig3}

###### Associations between epithelial or stromal CXCL14 expression and clinicopathological parameters, breast cancer subtypes, adjuvant therapy or stroma abundance

  **Number (CXCL14 data)**   ***N*****=498 (394)**                                                  
  -------------------------- ----------------------- ----------- --------- ------------ ----------- -------
  *n* (%)                    315 (80)                79 (20)               304 (77)     90 (23)      
  **Age (years)**                                                                                   
  ⩽50                        54 (13.8)               12 (3.0)    0.411     56 (14.0)    10 (3.0)    0.103
  \>50                       261 (66.2)              67 (17.0)             248 (63.0)   80 (20.0)    
  **Tumour size (mm)**                                                                              
  ⩽20                        182 (46.2)              51 (12.9)   0.274     183 (46.3)   50 (12.7)   0.432
  \>20                       133 (33.8)              28 (7.1)              121 (30.7)   40 (10.3)    
  **NHG**                                                                                           
  I                          70 (17.8)               23 (5.8)    0.212     75 (19.0)    18 (4.6)    0.431
  II                         129 (32.7)              30 (7.6)              121 (30.6)   38 (9.7)     
  III                        116 (29.5)              25 (6.3)              107 (27.1)   34 (8.7)     
  Missing                    0 (0)                   1 (0.3)               1 (0.3)      0 (0)        
  **Node status**                                                                                   
  Negative                   173 (43.9)              37 (9.4)    0.468     171 (43.4)   39 (9.9)    0.087
  Positive                   115 (29.1)              30 (7.6)              107 (27.1)   38 (9.7)     
  Missing                    27 (7.0)                12 (3.0)              26 (6.5)     13 (3.4)     
  **ER status**                                                                                     
  Negative                   55 (14.0)               4 (1.0)     0.006\*   47 (12.0)    12 (3.1)    0.620
  Positive                   260 (66.0)              75 (19.0)             257 (65.0)   78 (19.9)    
  **PR status**                                                                                     
  Negative                   107 (27.2)              19 (4.8)    0.091     102 (25.9)   24 (6.2)    0.219
  Positive                   208 (52.8)              60 (15.2)             202 (51.1)   66 (16.8)    
  **HER2 status**                                                                                   
  0                          180 (45.7)              39 (9.9)    0.777     173 (43.9)   46 (11.8)   0.577
  1                          69 (17.5)               26 (6.6)              70 (17.7)    25 (6.4)     
  2                          30 (7.6)                9 (2.2)               26 (6.5)     13 (3.3)     
  3                          32 (8.2)                3 (0.8)               29 (7.4)     6 (1.5)      
  Missing                    4 (1.0)                 2 (0.5)               6 (1.5)      0 (0)        
  **TNBC**                                                                                          
  No                         25 (6.4)                3 (0.8)     0.201     20 (5.0)     8 (2.0)     0.454
  Yes                        290 (73.6)              76 (19.2)             284 (72.0)   82 (21.0)    
  **Ki67 (%)**                                                                                      
  0--10                      103 (26.1)              34 (8.6)    0.049\*   109 (27.7)   28 (7.2)    0.416
  11--25                     101 (25.7)              25 (6.3)              97 (24.6)    29 (7.4)     
  \>25                       93 (23.6)               16 (4.1)              82 (20.7)    27 (6.9)     
  Missing                    18 (4.6)                4 (1.0)               16 (4.0)     6 (1.5)      
  **Subtype**                                                                                       
  Luminal A                  162 (41.2)              45 (11.4)   0.095     157 (39.8)   50 (12.6)   0.796
  Luminal B                  25 (6.3)                11 (2.7)              29 (7.3)     7 (1.7)      
  HER2                       22 (5.6)                1 (0.3)               20 (5.1)     3 (0.7)      
  Basal                      49 (12.4)               15 (3.8)              50 (12.7)    4 (1.0)      
  Missing                    57 (14.5)               7 (1.8)               48 (12.1)    16 (4.0)     
  **Adjuvant therapy**                                                                              
  No                         115 (29.2)              31 (7.9)    0.622     114 (28.9)   32 (8.1)    0.834
  Yes                        126 (32.0)              32 (8.1)              127 (32.2)   31 (7.9)     
  Missing                    74 (18.8)               16 (4.0)              63 (15.9)    27 (7.0)     
  **Stroma abundance**                                                                              
  1                          78 (19.9)               20 (5.1)    0.353     77 (19.5)    21 (5.3)    0.991
  2                          132 (33.5)              40 (10.2)             129 (32.7)   43 (11.0)    
  3                          97 (24.6)               18 (4.4)              90 (22.8)    25 (6.4)     
  Missing                    8 (2.0)                 1 (0.3)               8 (2.0)      1 (0.3)      

**Abbreviations**: ER=oestrogen receptor; NHG=Nottingham histological grade; PR=progesterone receptor; TNBC=triple-negative breast cancers.

*X*^2^ test for linear trend. Hormone receptor status was assessed by immunohistochemistry using a cutoff at 10% positive nuclei, according to current clinical guidelines in Sweden.

\**P*⩽0.05.

###### Multivariable analysis for survival data, including stromal CXCL14 expression

  **Number (CXCL14 data)**   ***N*****=498 (394)**                                                        
  -------------------------- ----------------------- --------------- ------------ ------- --------------- ------------
  **Age (years)**                                                                                         
  ⩽50                        1                                                    1                        
  \>50                       0.762                   0.411--1.412    0.388        0.731   0.451--1.184    0.203
  **Tumour size (mm)**                                                                                    
  ⩽20                        1                                                    1                        
  \>20                       1.619                   0.974--2.691    0.063        1.224   0.823--1.821    0.318
  **NHG**                                                                                                 
  I                          1                                                    1                        
  II                         2.289                   0.843--6.214    0.104        2.948   1.457--5.966    0.003\*
  III                        5.645                   2.139--14.900   \<0.0001\*   5.427   2.680--10.990   \<0.0001\*
  **Node status**                                                                                         
  Negative                   1                                                    1                        
  Positive                   4.155                   2.402--7.186    \<0.0001\*   2.482   1.657--3.717    \<0.0001\*
  **ER status**                                                                                           
  Negative                   1                                                    1                        
  Positive                   0.664                   0.320--1.376    0.271        1.005   0.546--1.851    0.987
  **HER2 status**                                                                                         
  0                          1                                                    1                        
  1                          1.393                   0.782--2.479    0.260        1.461   0.933--2.289    0.098
  2                          1.005                   0.422--2.398    0.990        1.206   0.623--2.335    0.578
  3                          0.774                   0.336--1.787    0.549        0.706   0.347--1.439    0.338
  **Stromal CXCL14**                                                                                      
  Negative                   1                                                    1                        
  Positive                   1.877                   1.123--3.138    0.016\*      1.602   1.050--2.443    0.029\*

**Abbreviations**: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; NHG=Nottingham histological grade; PR=progesterone receptor; TNBC=triple-negative breast cancers.

Cox regression analysis using stromal CXCL14 as categorical variable in multivariable analysis.

\**P*=\<0.05.
